Brenner M, Laragione T, Gulko PS. Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1␤, and NF-B activators' expression in pristane-induced arthritis. Physiol Genomics 45: 552-564, 2013. First published May 21, 2013 doi:10.1152/physiolgenomics.00029.2013Cia4 is a locus on rat chromosome 7 that regulates disease severity and joint damage in models of rheumatoid arthritis, including pristaneinduced arthritis (PIA). To identify molecular processes regulated by Cia4, synovial tissues from MHC-identical DA (severe erosive) and DA.F344(Cia4) congenics (mild nonerosive) rats were collected at preclinical and recent onset stages following the induction of PIA and analyzed for gene expression levels. Il6 levels were significantly higher in DA compared with congenics on day 10 (135-fold) after PIA induction (preclinical stage) and remained increased on days 14 (47.7-fold) and 18 (29.41-fold). Il6 increased before Il1b suggesting that Il6 could be driving Il1b expression and early synovial inflammation; 187 genes had significantly different expression levels and included inflammatory mediators increased in DA such Slpi (10.94-fold), Ccl7 (5.17-fold), and Litaf (2.09-fold). Syk or NF-B activating and interacting genes, including Cd74 Ccl21, were increased in DA; 59 genes implicated in cancer-related phenotypes were increased in DA. Genes involved in cell metabolism, transport across membranes, and tissue protection such as Dgat1, Dhcr7, and Slc1a1 were increased in DA.F344(Cia4) congenics; 21 genes differentially expressed or expressed in only one of the strains were located within the Cia4 interval and could be the gene accounting for the arthritis effect. In conclusion, the Cia4 interval contains at least one new arthritis gene that regulates early Il6, Il1b expression, and other inflammatory mediators. This gene regulates the expression of cancer genes that could mediate the development of synovial hyperplasia and invasion, and cartilage and bone destruction. autoimmunity; rheumatoid; genetic prognosis; positional RHEUMATOID ARTHRITIS (RA) is a common and potentially debilitating form of erosive arthritis. Recent advances in the understanding of RA pathogenesis have led to the development of new and better treatments (20, 32, 44 ). Yet disease remission is rarely achieved (45), and more effective therapies are needed. The identification of genes implicated in the regulation of arthritis severity and articular damage has the potential to generate new and better targets for therapies aimed at preserving joint architecture and function and reducing the risk of developing joint deformities. However, little is known about those genes (27), and the large cohorts of RA patients used in genome-wide association studies for susceptibility were not designed to address disease severity and articular damage.
autoimmunity; rheumatoid; genetic prognosis; positional RHEUMATOID ARTHRITIS (RA) is a common and potentially debilitating form of erosive arthritis. Recent advances in the understanding of RA pathogenesis have led to the development of new and better treatments (20, 32, 44) . Yet disease remission is rarely achieved (45) , and more effective therapies are needed. The identification of genes implicated in the regulation of arthritis severity and articular damage has the potential to generate new and better targets for therapies aimed at preserving joint architecture and function and reducing the risk of developing joint deformities. However, little is known about those genes (27) , and the large cohorts of RA patients used in genome-wide association studies for susceptibility were not designed to address disease severity and articular damage.
We have previously identified several disease severity and articular damage quantitative trait loci (QTL) in rat models of RA (5, 13, 17, 18, 36) . Using a combination of positional cloning, functional studies, and transcriptome analyses of synovial cells and synovial tissues, we are beginning to understand the molecular processes regulating arthritis severity and joint damage in pristane-and collagen-induced arthritis (PIA and CIA) (3, 5, (21) (22) (23) .
Cia4 is a 45.5 Mb QTL on rat chromosome 7 that regulates arthritis severity, cartilage and bone damage, synovial hyperplasia, and inflammation in both PIA and CIA (24, 36, 37) . To gain new insight into pathogenic and protective cellular pathways regulated by the arthritis gene located within the Cia4 interval we used synovial tissues from MHC-identical DA.F344(Cia4) congenics (arthritis-protected) and from DA (arthritis-susceptible) rats in a microarray analysis of gene expression. Tissues were obtained at very early stages during the development of PIA to identify early effects of the Cia4 locus on gene expression. We identified a new role for the Cia4 locus in the expression of several genes central to RA pathogenesis and joint damage, such as cytokines Il6 and Il1b, chemokines, protease inhibitors, genes implicated in the activation of the Syk and NFB pathways, and cancer-related genes.
MATERIALS AND METHODS

Animals
DA/BklArbNsi rats (DA) were originally purchased from Bantin & Kingman, maintained at Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, and then transferred to the Feinstein Institute for Medical Research (FIMR, formerly North Shore-LIJ Research Institute). DA.F344(Cia4) congenic rats ( Fig. 1) were generated based on genotype-guided breeding as previously described (36) . Briefly, alleles from arthritis-resistant F344 at the Cia4 interval on chromosome 7 were introgressed into arthritis-susceptible DA rats through eight genotype-guided backcrosses, while excluding F344 alleles at other arthritis-regulatory loci such as Cia1 (MHC on chromosome 20), Cia3 (chromosome 4), and Cia5 (chromosome 10). Rats heterozygous only at Cia4 were then intercrossed to generate homozygous. Rats homozygous at the congenic interval were brother-sister mated for at least five generations before conducting arthritis and microarray experiments. We used 8-to 12-wk-old rats in the arthritis and microarray experiments. All experiments involving animals were reviewed and approved by the FIMR Institutional Animal Care and Use Committee.
CIA
Purified bovine type II (BII) collagen (Chondrex, Redmond, WA) was dissolved in 0.1 N acetic acid (2 mg/ml) at 4°C and emulsified with incomplete Freund's adjuvant (IFA; Difco, Detroit, MI) to a final concentration of 1 mg/ml (12) . Anesthetized rats were injected with 2 mg/kg BII-IFA id at the base of the tail (day 0) and received a booster injection of 100 g 7 days later.
Arthritis Scoring
Arthritis severity was assessed with the arthritis severity index (ASI), an 80-point scoring system that measures disease severity over the course of 30 days postinduction of arthritis and correlates with the degree of synovial inflammation and with both cartilage and bone damage (4, 5) .
For the histology, microarray, and quantitative PCR (qPCR) experiments, female DA and DA.F344(Cia4) rats were scored daily from day 12 postinduction of PIA. Paws and synovial tissues were collected 24 h after the onset of moderate ankle arthritis (at least one ankle with score Ն2), or on day 18 for rats without moderate ankle arthritis. For additional qPCR experiments, synovial tissue was also collected 7, 10, and 14 days postinduction of PIA.
Histology
At the end of the arthritis observation period, rats were euthanized, and the hind paw with the most swollen ankle was fixed in 10% formaldehyde. Paws were then decalcified in hydrochloric acid and 0.1 M EDTA (Cal-Ex, Fisher Scientific), and ankles embedded in paraffin. Slides were prepared and stained with hematoxylin and eosin and scored without knowledge of strain identity. We used a previously described comprehensive histological scoring system (4 -5) where tibio-talar, talar-calcaneal, and midfoot joints were scored for the following parameters:
Synovial inflammation. Five high-power magnification fields (HMF) were scored for the percentage of infiltrating mononuclear cells as follows: 0, absent; 1, mild (1-10%); 2, moderate (11-50%); 3, severe (51-100%). The mean of the five HMF was used for analyses.
Synovial hyperplasia. 0, absent; 1, mild (5-10 layers); 2, moderate (11-20 layers); 3, severe (Ͼ20 layers).
Extension of articular surface covered by pannus. 0, absent; 1, incipient; 2, partial; 3, extensive.
Synovial fibrosis. 0, absent; 1, mild (1-10%); 2, moderate (11-50%); 3, severe (51-100%).
Synovial vascularity (angiogenesis). The mean number of vessels of five HMF. Fig. 2 . DA.F344(Cia4) congenics develop a significantly milder form of disease in pristane-(PIA) and collagen-induced arthritis (CIA). Male and female DA.F344(Cia4) congenic rats (OE) had significantly lower arthritis severity scores both in PIA (A and B) and CIA (D and E) compared with DA rats (). E: median arthritis severity index (ASI), which provides information of cumulative arthritis severity over time, was also significantly reduced in congenic males and females, both in PIA (C) and CIA (F). *P Յ 0.01, Mann-Whitney test for difference between arthritis severity scores at each time point and between ASI. Cartilage erosion. Percentage of the cartilage surface that was eroded: 0, absent; 1, mild (1-10%); 2, moderate (11-50%); 3, severe (51-100%).
Bone erosion. 0, none; 1, erosion(s) observed only at HMF; 2, erosion(s) observed at low magnification; 3, severe transcortical erosion(s).
RNA Preparation and Microarray Experiments
Synovial tissue total RNA was extracted with the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions including a DNase treatment step. RNA was quantified and assessed for purity using the NanoDrop spectrophotometer (Rockland, DE). RNA integrity was verified with the BioAnalyzer 2100 (Agilent, Palo Alto, CA).
Microarray. All reagents and procedures were previously optimized for use with the Illumina Whole-Genome Expression platform. Total RNA (200 ng) was amplified and biotinylated using the TotalPrep labeling kit (Ambion, Austin, TX). Samples were hybridized to the RatRef-12 Expression BeadChip (Illumina, San Diego, CA), which contains 22,522 probes covering 21,922 rat genes selected primarily from the NCBI RefSeq database (release 16). Hybridization was carried out in Illumina IntelliHyb chambers, followed by washing and staining with Cy3-streptavidin. The BeadChip was scanned on a high-resolution Illumina BeadArray reader with a two-channel 0.8 m resolution confocal laser scanner.
Microarray analysis. Fluorescence intensities were extracted using BeadStudio 2.0 (Illumina). To correct for systematic biases of nonbiological origin, background-subtracted intensities of all probes were normalized using the cubic spline algorithm followed by log 2-transformation. Probes consistently expressed in all arrays were used for analyses. Genes with a Ն1.5-fold difference in intensity between DA and DA.F344(Cia4) and a t-test P value Յ 0.01 were considered significantly differentially expressed and selected for pathway detection analyses using IPA 5.5.1 (Ingenuity Systems, Redwood City, CA), public online databases (GeneCards, Oncomine, BioGps, Ensembl), and literature (PubMed) search. Probes with a detection difference between strains of 60% or more were considered preferentially expressed and were also included in the analyses.
qPCR Expression Studies
Differences in the expression of selected genes were validated with qPCR. The qPCR conditions used have been described elsewhere (21) . Briefly, total RNA (200 ng) from each sample was reverse transcribed using Superscript III (Invitrogen). Primers and qPCR probes were designed to target the same exons as the corresponding Illumina RatRef-12 Expression BeadChip probes (Supplemental Table S1 ). 1 We used Universal ProbeLibrary (Roche, Indianapolis, IN) and Taqman (ABI, Applied Biosystems, Foster City, CA) probes labeled with FAM at the 5=-end and TAMRA at 3=-end. Reactions were prepared in duplicates with Eurogentec qPCR MasterMix (San Diego, CA), run on an ABI Prism 7700 thermocycler using SDS software version 1.9.1 (ABI). Ct (threshold cycle) values were adjusted for GAPDH in each sample (⌬Ct). Fold differences were calculated with the 2 Ϫ⌬⌬Ct method (25) . The same RNA samples used in the microarray experiments were used for qPCR validation. 1 ) had a significantly milder form of PIA compared with DA rats, with a reduction in the median ASI of 80.95% in males (P ϭ 0.006) and 93.10% in females (P Յ 0.001, Fig. 2, A-C) . DA.F344(Cia4) rats also had a significantly milder form of CIA, with a reduction in the median ASI of 60% in males (P ϭ 0.007) and 87% in females (P ϭ 0.003) compared with DA (Fig. 2, D-F ). These results demonstrate the impact of the Cia4 locus on the regulation of disease severity in both sexes and in two different models of autoimmune erosive arthritis. The protective effect of F344 alleles at Cia4 was detected as early as day 14 and persisted throughout the 31-day observation period. 1 The online version of this article contains supplemental material. Expression of IL-6, IL-1␤, and TNF-␣ was measured by quantitative (q)PCR using cDNA from synovial tissue collected 10 (DA n ϭ 8, Cia4 n ϭ 6), 14 (DA n ϭ 9, Cia4 n ϭ 7), or 18 days (DA n ϭ 5, Cia4 n ϭ 8) postinduction of PIA. *P Յ 0.05, #P Յ 0.008 (t-test).
Statistics
Histologic analyses of joints collected at day 18 postinduction of PIA, shortly after the onset of arthritis, revealed mild overall changes in DA. Inflammatory cell infiltration was reduced in synovial tissues from DA.F344(Cia4) congenic rats (mean score Ϯ SE ϭ 0 Ϯ 0) compared with DA (mean score ϭ 0.52 Ϯ 0.29; P ϭ 0.1). No other histologic differences were detected likely due to the very early stage in disease (Fig. 3) . 
Continued Decreased Expression of Proinflammatory Cytokines in DA.F344(Cia4) Congenic Rats
We aimed to detect very early changes in synovial tissue gene expression regulated by the Cia4 locus. Tissues were collected before disease onset (day 10 and day 14 postpristane injection) and shortly after disease onset (day 18) and checked for the expression of Il6, Il1b, and Tnfa, three central mediators of disease pathogenesis in rodent models of arthritis and in RA, by qPCR (Fig. 4) . We also examined the levels of these cytokines in synovial tissues from naïve DA rats (Supplemental Table S5 , DA day 0), and determined that Il6 (32.67-fold) and Il1b (2.36-fold) expression were significantly increased even when compared with synovial tissues obtained from DA.F344(Cia4) congenics with PIA collected at day 10. These results demonstrate that a gene located within the Cia4 interval regulates the baseline levels of these cytokines even in naïve rats. At day 10, Il6 levels were 135-fold higher in synovial tissues of DA compared with DA.F344(Cia4) congenic rats (P ϭ 0.008), and levels remained significantly increased in DA at day 14 (47.7-fold, P Յ 0.001) and at day 18 (29.4-fold, P ϭ 0.011).
Synovial expression of Il1b was also significantly higher in DA rats at days 14 (4.21-fold, P Յ 0.001) and 18 (2.97-fold, P ϭ 0.045), but not at day 10 (1.37-fold, P ϭ 0.66). The observation that Il6 levels increased before those of Il1b suggests that Il6 may be driving the Il1b expression and could be more directly regulated by the arthritis gene located within the Cia4 interval.
Synovial expression of Tnfa was initially reduced in DA by 0.45-fold (P ϭ 0.043) at day 10 compared with DA.F344 (Cia4) congenics, and increased modestly as disease progressed to 1.54-fold at day 18 (not significant with P Ͼ 0.05). The significance of this mild early increase of Tnfa levels in the protected strain is of unclear relevance.
Synovial Tissues From DA.F344(Cia4) Congenics With Recent-onset Arthritis Have a Distinct Gene Expression Signature
To evaluate the effect of Cia4 on the synovial transcriptome of recent-onset arthritis, we collected synovial tissues from six DA and six DA.F344(Cia4) female rats with PIA within 24 h of onset of definitive ankle arthritis (score Ն 2 on a scale of 0 -4). Only one DA.F344(Cia4) had ankle arthritis score of 2 by day 18, which is 4 days after the typical day of onset of PIA, and all six congenics were euthanized for tissue collection and RNA extraction at that point. All six DA and six DA.F344(Cia4) congenics were used in the microarray and qPCR validation experiments and analyses.
We found 6,928 genes to be expressed in synovial tissues of all rats. A total of 187 genes met the criteria for significance and were differentially expressed between DA and DA.F344(Cia4) synovial samples. Of the 125 genes with increased expression in DA, 33 are involved in inflammatory and immune responses; 62 genes are increased in DA.F344(Cia4) ( Tables 1-3, Supplemental Table S2) .
Inflammatory mediators. The most significantly increased expression in DA rats and therefore reciprocally reduced expression in DA.F344(Cia4) synovial tissues were the protease inhibitor Slpi (10.94-fold) and its receptor Plscr1 (2.31-fold) (35) , the macrophage and monocyte scavenger receptor Cd163 (5.85-fold), the C-C chemokine Ccl7 (5.17-fold) and Lst1 (4.97-fold) (Tables 1-3, Fig. 5A ). These genes have been previously found to be expressed in increased levels in synovial tissues or blood cells from either rodent models of arthritis or from patients with RA (1, 3, 8, 14, 30, 33, 39) . These similarities with RA underscore the relevance of our observations and point to a potential role of the arthritis severity gene located in the Cia4 interval in the regulation of these events in human disease also. Cd163 is a macrophage-specific gene. Macrophage and other myeloid cells are also the predominant source of Ccl7 and Lst1, suggesting increased number or increased activation either of synovial macrophages or of infiltrating macrophages, neutrophils, and dendritic cells in DA. DA.F344(Cia4) synovial tissues also had reduced levels of the TNF␣-inducing factor Litaf (2.09-fold), which regulates TNF-␣ and IL-6 levels and was recently shown to be an important mediator of arthritis severity and joint damage (28) . Nine genes involved in respiratory burst were expressed in increased levels in DA (Table 2) .
There were 27 genes involved in the activation of the Spleen tyrosine kinase (Syk) or NFB, or known to interact with these two genes and pathways expressed in increased levels in DA in significantly reduced levels in congenics, suggesting that the arthritis gene located in the Cia4 interval is involved in the regulation of these signaling pathways (Fig. 5A) . These Syk or NFB-interacting/activating genes and immune and inflammatory responses included Cd74 (2.60-fold), which is involved in (Tables 1-3) .
Rpl30 was the gene with the most significantly increased expression in DA.F344(Cia4) congenics (92-fold higher), compared with DA (Tables 1 and 4) . The increased expression of Rpl30 in congenics was confirmed with qPCR; however, levels were at a less striking difference (1.57-fold, P ϭ 0.038; Fig. 6 ).
The differential expression and fold-difference of a selected group of genes was confirmed with qPCR ( Fig. 6) . These included Cpa3, Cysltr1, Ifi204, P2rx5, Parva, Ptgs2, Rrp7a, Tprkb, and Tpsb2.
Genes involved in metabolism and tissue protection. Other genes with increased expression ranging from 1.5-to 3-fold in DA.F344(Cia4) included those related to lipid and mitochondrial metabolism (Acat1, Dgat1, Dhcr7), the palmitoylcarnitine mitochondrial transporter Slc25a29, and the transmembrane glutamate and aspartate transporter Slc1a1 (required to prevent neurocytotoxicity induced by this neurotransmitter), and the inhibitor of oxidation Nqo1 (Table 4 , Fig. 5B) . Together, these genes suggest an increased expression of genes involved in metabolism and centered around insulin and Pdgf pathways as suggested by Ingenuity pathway analyses (Fig. 5B) , and anti- oxidative genes in synovial tissues from DA.F344(Cia4) congenics. Cancer, tumorigenesis, and genes involved in cell proliferation. Fifty-nine of the genes expressed in increased levels in DA, including Cdk4, Fgf7, Itgb2, Rhog, Syk, Tryrobp, and others, have also been implicated in the regulation of cell proliferation, tumorigenesis, or cancer (Supplemental Table S3 ). These genes were expressed in reduced levels in DA.F344(Cia4) congenics, suggesting that a gene located within the congenic interval directly or indirectly regulates these genes and could be affecting the ability of the synovial tissue to proliferate (synovial hyperplasia) and invade and erode cartilage and bone.
Strain-specific gene expression. Strain-specific synovial tissue gene expression could provide critical information about the identity and function of the arthritis gene located within the Cia4 interval. To quantify this difference in detection, we considered preferentially expressed genes those that were detected with a difference of at least 60% between DA and DA.F344(Cia4) (4 and 0, 5 and 0, 5 and 1, 6 and 0, 6 and 1, and 6 and 2) ( Table 5) . We found 130 genes to be preferentially expressed in DA and 58 genes in DA.F344(Cia4). Similarly to differentially expressed genes, 23 of the genes preferentially expressed in DA included cytokines and cytokine receptors (Il1rn, Il2ra, Il10, Il21r), signal transduction molecules implicated in inflammatory responses (Itk, Lck, Traf4), chemokines and chemokine receptors (Ccl20, Ccr2, Cx3cr1), members of the T cell receptor complex (Cd3d, Cd8b), adhesion molecules (Cd84, Sell), and genes encoding members of the innate immune response (Card11, Cfi, Nlrp3, Nlrc4, Ptger4, Tlr4). Sixteen genes implicated in NF-B activation were also among the genes preferentially expressed in DA, further adding to the list of NF-B-interacting/activating genes with significant difference between these two strains.
Five genes were expressed in all DA synovial tissues but in none of the tissues from DA.F344(Cia4) congenics (P ϭ 0.002). These included Slc25a32, a mitochondrial folate carrier, the Rho GTPase activating protein Arhgap8, the phospholipase Pla2g7, the immunoreceptor Ly49si1 and Susd1 (Table 5 ).
The gene with most significant preferential expression in DA.F344(Cia4) congenics was Parvalbumin (Pvalb), a calciumbinding protein with properties and activity similar to calmodulin, but with unclear function in the synovial tissues or inflammatory cells. Pvalb was expressed in all synovial tissues from DA.F344(Cia4) congenics but in none of the DA tissues (P ϭ 0.002) ( Table 5 ). 
Continued
Differentially expressed (or strain-specific genes) located within the Cia4 interval. A total of 11 differentially expressed genes and 10 of the preferentially expressed genes mapped to the Cia4 region (Table 6) . Genes with increased expression in DA.F344(Cia4) congenics were more likely to be located within the Cia4 interval, as opposed to those not differentially expressed (8.06 and 2.97%, respectively, P ϭ 0.05, 2 ).
DISCUSSION
Genetic factors have a major role in RA disease severity and joint damage (19) , yet little is known about the specific identity of those genes (27) . These arthritis severity and joint damage genes have the potential to become major targets for drug therapy and important prognostic biomarkers and we have focused our efforts on their discovery. Cia4 is a quantitative trait locus previously shown to regulate disease severity in three well-established models of RA, oil-induced arthritis, CIA, and PIA (36, 37) . The human chromosomal regions syntenic to Cia4 are located in parts of chromosomes 8, 12, and 22 and are not known contain any human RA susceptibility or severity gene. However, RA severity and joint damage have not been systematically studied in a genome-wide manner, and therefore those human chromosomal regions simply have not been probed yet. In the present study we analyzed DA.F344(Cia4) congenics, which share most of their genome with DA rats (including the MHC), except for the Cia4 interval on chromosome 7. The simple presence of F344 alleles at the 45.5 Mb Cia4 interval was enough to significantly reduce arthritis severity on both sexes and to reduce joint inflammation even at a very early stage in the disease course. This observation underscores the major effect of the arthritis gene located within Cia4 on disease pathogenesis and severity.
Analyses of gene expression in synovial tissues of rats with PIA revealed a peak of 135-fold increase in mRNA levels of Il6 in DA at an early and preclinical stage, compared with DA.F344(Cia4) congenics. Il6 levels remained increased in all three time-points from preclinical to recent onset disease. Tnfa levels were not significantly different between these two strains, suggesting that Tnfa is not mediating the protective effect in DA.F344(Cia4) congenics. Il1b levels increased days after Il6 and at a lower magnitude, suggesting that Il6 was a major early driver of both arthritis and Il1b expression in synovial tissues. These results suggest that the arthritis severity gene located within the Cia4 interval is a new regulator of the Il6 expression via a yet unidentified mechanism. Syk (7, 15, 43) and NF-B (11, 29, 38, 41, 46) pathways are central to the pathogenesis and joint damage in RA and in rodent models of RA. Therefore, it was interesting that the list of genes expressed in increased levels or preferentially expressed in DA compared with DA.F344(Cia4) congenics included many genes that interact with these two pathways or are involved in their activation. While the number of Syk pathway genes detected in this study was not as high as that described in analyses of another congenic strain DA.F344(Cia5a) (2), our observations suggest a novel direct or indirect role for the arthritis gene located within the Cia4 interval in the regulation or activation of both Syk and NF-B pathways, and it is conceivable that this may be the Cia4-mediated mechanism regulating the differential expression of Il6 in these two strains.
Slpi was the gene with the most significantly increased expression in DA and reciprocally reduced expression in congenics. The Slpi receptor Plscr1 (35) was also expressed in increased levels in DA. Slpi typically protects tissues from serine proteases but can also increase the expression of MMP-2 and tumor cell invasion (6) . Slpi was previously found in increased levels in synovial tissues of rats with PIA (2) and in Streptococcal cell wall-induced arthritis (SCWIA) (39) . Its exogenous administration reduced levels of TNF-␣ and joint damage in SCWIA (39) . These observations suggest that the increased expression of Slpi and its receptor in DA synovial tissues might represent a failed or insufficient attempt at reducing inflammation and joint damage, perhaps due to insufficient protein synthesis. As a soluble protein, Slpi could be a potentially interesting candidate for therapeutic use in RA.
Several inflammatory mediators were also expressed in increased levels in synovial tissues from DA and reduced in DA.F344(Cia4) congenics. Those included genes preferentially expressed by myeloid cells such as Ccl7, Cd163, and Lst1. Ccl7 is expressed in increased levels in synovial tissue from RA (14) and in rodent models of arthritis (1, 3) . It is a chemoattractant for macrophages, dendritic cells, and activated T cells, and two of its receptors, Ccr1 and Ccr2, were also expressed in increased levels in DA, supporting the potential relevance of this axis for cell migration into the synovial tissues at very early stages of arthritis development. Interestingly, Ccl7 has not yet been targeted for therapy in arthritis or other inflammatory diseases, and our results raise it as potentially important.
Ccl21 was also increased in DA compared with congenics. This gene is expressed in increased levels in RA synovial tissues and induces angiogenesis (34) and lymphoid aggregation (26) . Polymorphisms in Ccl21 have also been associated with RA susceptibility (40) and with premature mortality in RA (9) , underscoring the role of this gene in disease pathogenesis and outcome. Like Ccl7, Ccl21 has not yet been targeted for therapy in RA.
Levels of the TNF-␣-inducing factor Litaf were significantly increased in DA compared with congenics. To our knowledge Litaf has not yet been studied in RA, but it was recently shown that Litaf knockout mice are significantly protected in collagen antibody-induced arthritis, developing reduced inflammation and articular damage (28) , and suggesting that the increased expression we detected in early stages during disease course could in fact be involved in arthritis pathogenesis and joint damage.
We (16, 21) and others (10, 31) have previously described the increased expression of several genes implicated in cancerrelated phenotypes such as cell invasion, proliferation, and metastasis in synovial tissues of arthritic joints. It is considered that those cancer-related genes favor increased synovial cell proliferation, synovial hyperplasia, increased synovial fibroblast invasion, and increased production of proteases that contribute to joint erosion and damage. In this study we identified yet another set of cancer-related genes, different from our previous reports in studies with the DA.F344(Cia5d) and DA.ACI(Cia10) congenics, suggesting that each arthritis severity gene/locus regulates a unique set of genes to cause synovial hyperplasia, synovial invasion, and joint damage, like phenocopies.
Rpl30 and other genes encoding ribosomal proteins, genes implicated in metabolism and transport across membranes, and genes implicated in tissue protection were expressed in increased levels in synovial tissues from DA.F344(Cia4) congenics, suggesting that preserving anabolic metabolism might have a protective role in arthritis or that, conversely, the pathogenic processes taking place in DA synovial tissues inhibit those processes favoring catabolism and increased oxidative and tissue damage.
The analyses of strain-specific gene expression revealed several additional unique and highly relevant differences. While those differences included proinflammatory and signaling mediators and additional cancer-related and cell cycle regulatory genes, these analyses also generated insight into the potential identity of the arthritis severity gene located within the Cia4 interval. Specifically, nine of the genes preferentially expressed in one strain and not in the other were located within the Cia4 interval, suggesting that they could be the actual disease-regulatory gene. Eleven of the differentially expressed genes also mapped to the Cia4 interval. We are currently sequencing these genes and looking for disease-causing variants at coding and noncoding regions, particularly at regulatory elements [5=-untranslated region (UTR) and 3=-UTR] that might explain the differences in expression. Once discovered, these new sequencing variants will be studied to determine their functional consequence and role in arthritis.
Lastly, we considered the possibility that at least part of the differential or preferential gene expression could be secondary to differences in synovial cellularity. We looked for genes specific for T cells (CD4ϩ, CD8ϩ), Tregs, NK cells, B cells, neutrophils, macrophages, dendritic cells, adipocytes, and endothelial cells. However, we did not detect an overrepresentation of cell-specific genes in either DA or DA.F344(Cia4) congenics, suggesting that the differences identified at this very early stage in the course of PIA were more likely due to increased or decreased cell activation/function and not due to obvious differences in cellularity.
In conclusion, we have determined that the arthritis gene located within the Cia4 locus is an early regulator of the expression of several key mediators of arthritis pathogenesis and joint damage. These new discoveries should facilitate the identification of the gene accounting by the Cia4 effect in arthritis and are anticipated to generate new targets for therapy and potential new prognostic biomarkers.
GRANTS
Funded by the National Institutes of Health Grants R01-AR-46213, R01-AR-052439, and R01-AI-54348 to P. S. Gulko.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
Author contributions: M.B. and P.S.G. performed experiments; M.B., T.L., and P.S.G. analyzed data; M.B. and P.S.G. prepared figures; M.B., T.L., and P.S.G. edited and revised manuscript; M.B., T.L., and P.S.G. approved final version of manuscript; T.L. and P.S.G. interpreted results of experiments; P.S.G. conception and design of research; P.S.G. drafted manuscript.
